The Prescribe Right Pharmaceutical Pipeline Tracker is working to provide information that subscribers can use in updating their Emergency Operations Plan to provide contingencies for COVID-19.  There are no approved treatments for COVID-19. But several researchers and pharmaceutical companies are conducting or designing clinical trials to test potential treatments.

We currently are tracking drugs and vaccines for the treatment or prevention of COVID-19 infections in the pages listed below. Whenever possible, we have included published information or grey literature announcements for clinical results. We also include dosing used in clinical trials or reported in cases or case series, clinical trials for the drug, and information on expanded access programs if one exists. Our COVID-19 pages can be accessed by clicking on the link below or through the drop-down menu under COVID-19.

Current Updates for COVID-19
Vaccines being developed to prevent COVID-19
​Antivirals being developed to treat COVID-19
​Blood-derived products under evaluation for the treatment of COVID-19
Anti-Inflammatories being tested to treat cytokine storm associated with severe and critical COVID-19 
Remdesivir Expanded Summary
Chloroquine & Hydroxychloroquine Expanded Summary

​ COVID-19 Preparedness Resources

The NIH provides guidelines for the treatment of patients with COVID-19 that are continuously updated. A list of updates and recommendations by date of publication are provided to help health care practitioners stay current. The guidelines include an Overview of Therapeutic Management of Patients with COVID-19, based on disease severity. There is also a review of evidence that supports or refutes the use of therapies and a recommendation by NIH for or against use of the therapies.
 
Current treatment recommendations are organized by severity of disease in an easy-to-use graphic.
  • Non-hospitalized or hospitalized patients not on supplemental oxygen should not receive remdesivir or dexamethasone
  • Hospitalized patients requiring supplemental oxygen, but not high flow oxygen or ventilation should receive remdesivir for five days. The duration can be extended for up to ten days and dexamethasone added. Dexamethasone alone can be used if remdesivir is not available.
  • Hospitalized patients requiring high-flow oxygen or non-invasive ventilation should receive 5-10 days of remdesivir and dexamethasone or dexamethasone for up to ten days
  • Hospitalized patients requiring mechanical ventilation or ECMO dexamethasone for up to ten days or 5-10 days of remdesivir and dexamethasone in patients that have recently been intubated.
FDA COVID-19 Resource Page

CDC COVID-19 Resources Home Page
 
CDC Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)
 
Comprehensive Hospital Preparedness Checklist for Coronavirus Disease 2019 (COVID-19)
 
CDC Resources for Hospitals and Healthcare Professionals Preparing for Patients with Suspected or Confirmed COVID-19
 
World Health Organization (WHO): Coronavirus disease (COVID-19) technical guidance

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

The Society of Critical Care Medicine Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) 

The American Thoracic Society COVID‐19: Interim Guidance on Management Pending Empirical Evidence 

JAMA: Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Infectious Diseases Society of America Guidelines on Infection Prevention in Patients with Suspected or Known COVID-19

Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 19) Treatment

ASHP Coronavirus Disease 2019 (COVID-19) Resource Page
 
ASHP Review of Evidence for COVID-19 Treatments
 
Johns Hopkins COVID-19 case counts by country
 
NEJM COVID-19 resources
 
JAMA COVID-19 Resource Center
 
JAMA COVID-19 ICU Care Review
 
Online References
 
Information on Investigational Drugs to Treat COVID-19 - Because information is announced or published on almost a daily basis, be sure and check the revision date. These sources currently do not include information on investigational monoclonal antibody, immunoglobulin or vaccines, which can be found in the Prescribe Right COVID-19 Investigational Drug Tracker.
  • The drugs references such as Facts & Comparisons, Micromedex, Lexicomp and Clinical Pharmacology have added information regarding some of the drugs being investigated to treat COVID-19. Epocrates also has information in a special section under guidelines. 
  • Both UpToDate and Dynamed have monographs on diagnosis and management of COVID-19 patients.
  • Evidenced based review of investigational drug for COVID-19

Subscribe to our knowledgebase to have the most current information investigational drugs by going to our subscription page or arrange for a demonstration of the Pharmaceutical Pipeline Tracker by going to our contact page.